RADIOIODINE THERAPY OF THYROTOXICOSIS THE MONTEFIORE EXPERIENCE

Radioiodine therapy in thyrotoxicosis.

One hundred and two patients (81 females, 21 males) suffering from thyrotoxicosis as diagnosed clinically and confirmed by laboratory investigations including the estimation of thyroid hormones in blood were treated with radioiodine (I-131) at the University of Minnesota Hospital between 1976 and 1986. Nine (9%) patients needed two and 3 (3%) patients needed three therapeutic doses of I-131. Th...

Radioiodine therapy in patients with type II amiodarone-induced thyrotoxicosis.

INTRODUCTION The treatment of amiodarone-induced thyrotoxicosis (AIT) still remains a clinical challenge, requiring the cooperation of both endocrinologists and cardiologists. Unfortunately, even today AIT is related to significantly increased mortality. OBJECTIVES The aim of this study was to compare the efficacy of radioidine therapy for type II AIT in 2 groups of patients: with high or nor...

Risks from radioiodine treatment of thyrotoxicosis.

Atrial fibrillation in thyrotoxicosis treated with radioiodine.

RADIOACTIVE Iodine (131I) is frequently recommended as the treatment of choice for thyrotoxicosis in patients over 45 years old without sufficient appreciation of the difficulties in management that occasionally occur. The increasing frequency of post-radiation myxoedema is now widely recognised (Green and Wilson, 1964) but less emphasis has been paid to the situation in some subjects in whom t...

Evaluation of Radioiodine Therapy in the Refractory Hyperthyroidism

Background: Thyrotoxicosis is a clinical state with potentially multiple etiologies, clinical presentations, and treatments. Thyrotoxicosis is a clinical condition that results from inappropriate function of thyroid hormone in the body tissues. During the early 1950s, radioactive iodine was used as a definitive treatment method. During the last two decades, radioactive iodine has been recognize...